Clinical Trials
173
29 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1876
Completed
108
62.4%
Not yet recruiting
29
16.8%
Recruiting
35
20.2%
No approval data available
- Researchers identified the azc biosynthetic gene cluster that is necessary and sufficient for assembling the 1,3,5-triazine nucleobase of the anticancer drug 5-azacytidine. - The pathway hinges on AzcA, a cupin domain-containing enzyme that cleaves and reassembles the pyrimidine ring into a triazine through enzymatic skeletal editing. - AzcE, a GTP cyclohydrolase, and the thiamine pyrophosphate-dependent AzcB/C pair complete the cascade, which was resolved with X-ray crystallography, cryo-EM and DFT calculations. - The findings could enable biocatalytic or fermentative manufacturing of 5-azacytidine and guide genome mining for new triazine natural products.
- Researchers at Hokkaido University developed e-MITO, a surface engineering approach that coats isolated mitochondria with PEG and cell-penetrating peptides to enhance stability and cellular uptake. - In laboratory experiments, CPP–PEG-engineered mitochondria were taken up more efficiently by cells than unmodified mitochondria and led to increased mitochondrial respiratory activity in recipient cells. - The modular design could enable mitochondria to be targeted to specific diseases or tissues, representing an early step toward using organelles as therapeutic tools. - The study, led by Professor Yuma Yamada, was published in Advanced Materials Interfaces and supported by JST FOREST Program and AMED.
- A novel study reveals that HYA, a gut microbiome-derived metabolite, effectively reduces post-meal blood sugar spikes in type 1 diabetes model rats through multiple mechanisms. - Researchers from Wakayama Medical University, Hokkaido University, and Noster Inc. demonstrated that HYA enhances gut hormone secretion and inhibits glucose absorption without triggering inflammatory responses. - When combined with standard insulin therapy, HYA provided additional improvements in postprandial glucose control, suggesting potential as a complementary approach to traditional diabetes management.
- Shionogi's SCORPIO-PEP Phase 3 trial demonstrated ensitrelvir reduces COVID-19 risk by 67% in exposed household contacts, making it the first oral antiviral to successfully prevent COVID-19 after exposure. - The study included over 2,000 participants who received either ensitrelvir or placebo within three days of household exposure, with only 2.9% of treated individuals developing COVID-19 compared to 9.0% on placebo. - Ensitrelvir received FDA Fast Track designation for post-exposure prophylaxis in 2025 and could fill a critical unmet need, particularly for immunocompromised individuals and in healthcare settings.
